I feel that this will be JP and SN legacy so takeover will be...

First 44 Last

Share
Profile

Follow
max99

503 Posts.

88

03/09/19

10:36

Post #: 40287833
Share

Originally posted by Heskumdai: ↑

Maybe, seems logical that STX get's taken out, but I'm not getting too far ahead of myself in thinking this - and as a STX shareholder might not want it?

My thinking is that if WE + Jaws come off then STX may become a mid-tier firm worth some $2-$4B...possibly. At that level they may be worth nearly as much as Beach ($5B), so can Beach actually swallow them?

But, I think it might be that this mgt team can add more value by getting production going. Their skills set has been impressive so far, so I wouldn't put it beyond them. If they get to 60c, which is possible with WE, raise 10% - or $100m - then they have a fair bit of funding to drill a few more wells and explore those 8 options they've been talking about. I don't think they'd have problems getting the $'s (likely from insto) and so it's a real possibility. If they drill another 8 wells then the value is much higher than Beach is likely to pay now, which is why Beach would do the transaction, but I feel this mgt team are not out for soft / quick $. They want to build something meaningful, which is the language they're using (as you'd expect they would).

So, i'm expecting people to come to the table, but I'm hoping management make a go of it and add more value over the next 2-3 years by developing WE and proving JAWS before selling. Now that scenario may make a lot of $'s for shareholders? Likely more than someone will pay up-front. Just my thoughts.

Expand

I feel that this will be JP and SN legacy so takeover will be out the question imo

STX Price at posting: 28.5¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 28 more messages in this thread...

First 44 Last

Add STX (ASX) to my watchlist

(20min delay)
Last 22.8¢		Change -0.003(1.09%)		Mkt cap ! $659.0M

Open	High	Low	Value	Volume
23.0¢	23.0¢	22.5¢	$479.2K	2.100M

Buyers (Bids)

No.	Vol.	Price($)
58	1535599	22.5¢

Sellers (Offers)

Price($)	Vol.	No.
23.0¢	4971648	70

View Market Depth

No.	Vol.	Price($)
60	1553765	0.225
22	1300745	0.220
17	1322694	0.215
28	1852474	0.210
33	1614673	0.205

Price($)	Vol.	No.
0.230	4979919	69
0.235	1675973	24
0.240	1536839	19
0.245	1034404	21
0.250	2238905	28

Last trade - 15.36pm 07/10/2024 (20 minute delay)

STX (ASX) Chart

I feel that this will be JP and SN legacy so takeover will be...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I feel that this will be JP and SN legacy so takeover will be...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News